Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), retaining the price target of $35.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors surrounding Liquidia Technologies. The imminent PDUFA date for Yutrepia, their lead asset for PAH and PH-ILD, is a significant catalyst, especially with the expected loss of exclusivity for United Therapeutics’ Tyvaso. Recent legal victories, including favorable rulings in the ongoing litigation with United Therapeutics and the FDA, have strengthened Liquidia’s position and reduced uncertainties.
Additionally, the potential resolution of the ‘327 patent infringement case in favor of Liquidia could further eliminate legal overhangs, paving the way for a de-risked path forward. The market opportunity for PH-ILD appears particularly promising, and expert opinions highlight Yutrepia’s strong efficacy and tolerability profile. These factors collectively contribute to a positive outlook for Liquidia’s commercial launch and overall stock performance.
According to TipRanks, Jubinville, PhD is an analyst with an average return of -5.6% and a 40.00% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Tenaya Therapeutics, and Crinetics Pharmaceuticals.
In another report released today, Raymond James also maintained a Buy rating on the stock with a $29.00 price target.